Drug Profile

Research programme: cyclosporin-based mitochondrial protective therapeutics - Abliva/Guard Therapeutics

Latest Information Update: 05 Jun 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator A1M Pharma AB; NeuroVive Pharmaceutical
Developer Abliva; Guard Therapeutics
Class Ciclosporins
Mechanism of Action Calcineurin inhibitors; Cyclophilin D inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 May 2020 NeuroVive Pharmaceutical is now called Abliva
28 Apr 2018 No recent reports of development identified for research development in Mitochondrial disorders in Sweden
25 Mar 2014 Early research in Mitochondrial disorders in Sweden (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com